Skip to content
Screener

Immunovant, Inc. IMVT Q4 2026 Annual earnings

Reported May 20, 2026 · Before market open

EPS-$0.73Miss by $0.13
EPS estimate-$0.60

Next report

Nov 9, 2026 (in 2 months)
Revenue estimate$7.1M
EPS estimate-$0.73

Financials

Q4 2026

Income statement

See full
Net income-$147.9M-38.9%
EPS (diluted)-$0.73-15.9%

Balance sheet

See full
Cash & equivalents$902.1M+26.4%
Total debt$72.0K-26.5%
Total equity$852.6M+20.5%
Total assets$957.0M+23.3%

Cash flow

See full
Operating cash flow-$95.1M+14.1%
CapEx$8.0K-96.0%
Free cash flow-$95.1M+14.2%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$5.06B+74.2%
Enterprise value$4.15B+89.7%

Returns & leverage

See full
Return on equity-64.8%+2.5pp
Debt / equity0×0.0×
Current ratio9.1×-2.1×

FAQ

When did Immunovant, Inc. report Q4 2026 earnings?
Immunovant, Inc. (IMVT) reported Q4 2026 earnings on May 20, 2026 before market open.
What were Immunovant, Inc.'s Q4 2026 revenue and EPS?
Immunovant, Inc. reported eps of $-0.73 for Q4 2026.
Did Immunovant, Inc. beat estimates in Q4 2026?
EPS missed the consensus estimate of $-0.60 by $0.13.
How did Immunovant, Inc.'s Q4 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 14.1% from $-0.64.
Where can I find Immunovant, Inc.'s Q4 2026 SEC filings?
You can read the 8-K earnings release (0001764013-26-000062) and the 10-K periodic report (0001764013-26-000064) directly on SEC EDGAR. The filing index links above go to sec.gov.